Novavax, Inc. (NVAX)
NASDAQ: NVAX · IEX Real-Time Price · USD
4.785
+0.075 (1.59%)
May 3, 2024, 11:19 AM EDT - Market open
Novavax Revenue
In the year 2023, Novavax had annual revenue of $983.71M, a decrease of -50.36%. Revenue in the quarter ending December 31, 2023 was $291.34M, a -18.48% decrease year-over-year.
Revenue (ttm)
$983.71M
Revenue Growth
-50.36%
P/S Ratio
0.67
Revenue / Employee
$637,528
Employees
1,543
Market Cap
671.83M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
Dec 31, 2019 | 18.66M | -15.63M | -45.57% |
Dec 31, 2018 | 34.29M | 3.11M | 9.98% |
Dec 31, 2017 | 31.18M | 15.82M | 103.06% |
Dec 31, 2016 | 15.35M | -20.90M | -57.65% |
Dec 31, 2015 | 36.25M | 5.59M | 18.24% |
Dec 31, 2014 | 30.66M | 9.74M | 46.59% |
Dec 31, 2013 | 20.92M | -1.16M | -5.26% |
Dec 31, 2012 | 22.08M | 7.39M | 50.30% |
Dec 31, 2011 | 14.69M | 14.35M | 4,182.22% |
Dec 31, 2010 | 343.00K | 18.00K | 5.54% |
Dec 31, 2009 | 325.00K | -739.00K | -69.45% |
Dec 31, 2008 | 1.06M | -449.00K | -29.68% |
Dec 31, 2007 | 1.51M | -225.00K | -12.95% |
Dec 31, 2006 | 1.74M | -3.61M | -67.47% |
Dec 31, 2005 | 5.34M | -2.92M | -35.31% |
Dec 31, 2004 | 8.26M | -3.53M | -29.91% |
Dec 31, 2003 | 11.79M | -3.22M | -21.46% |
Dec 31, 2002 | 15.01M | -9.06M | -37.65% |
Dec 31, 2001 | 24.07M | 21.59M | 872.36% |
Dec 31, 2000 | 2.48M | 1.29M | 109.57% |
Dec 31, 1999 | 1.18M | 500.00K | 73.42% |
Dec 31, 1998 | 681.00K | 161.00K | 30.96% |
Dec 31, 1997 | 520.00K | 464.00K | 828.57% |
Dec 31, 1996 | 56.00K | -212.00K | -79.10% |
Dec 31, 1995 | 268.00K | -416.88K | -60.87% |
Dec 31, 1994 | 684.88K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cross Country Healthcare | 2.02B |
Fulgent Genetics | 289.21M |
Quanterix | 122.37M |
Wave Life Sciences | 113.31M |
Zymeworks | 76.01M |
Jin Medical International | 19.82M |
NVAX News
- 22 hours ago - Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement - Accesswire
- 18 days ago - Hedge fund Shah Capital recommends two new candidates for Novavax board - Reuters
- 18 days ago - Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says - Market Watch
- 4 weeks ago - Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024 - PRNewsWire
- 2 months ago - Novavax to Participate in TD Cowen's 44th Annual Health Care Conference - PRNewsWire
- 2 months ago - Novavax Stock Sinks as Revenue Misses Estimates in ‘Transition Year' - Barrons
- 2 months ago - Novavax sees 2024 sales flat to lower, aims to pick up COVID vaccine market share - Reuters
- 2 months ago - Novavax misses quarterly estimates, but vaccine maker narrows losses as it slashes costs - CNBC